Cargando…

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

Activating JAK2 point mutations are implicated in the pathogenesis of myeloid and lymphoid malignancies, including high-risk B-cell acute lymphoblastic leukemia (B-ALL). In preclinical studies, treatment of JAK2 mutant leukemias with type I JAK2 inhibitors (e.g., Food and Drug Administration [FDA]-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sang-Kyu, Knight, Deborah A., Jones, Lisa R., Vervoort, Stephin, Ng, Ashley P., Seymour, John F., Bradner, James E., Waibel, Michaela, Kats, Lev, Johnstone, Ricky W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory Press 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049517/ https://www.ncbi.nlm.nih.gov/pubmed/29907650 http://dx.doi.org/10.1101/gad.307504.117

Ejemplares similares

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
por: Downes, Charlotte E. J., et al.
Publicado: (2021)

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S, et al.
Publicado: (2018)

Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development
por: Roncero, A M, et al.
Publicado: (2016)

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S., et al.
Publicado: (2018)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

Epigenetic changes in inflammatory arthritis monocytes contribute to disease and can be targeted by JAK inhibition
por: Peeters, Janneke G C, et al.
Publicado: (2023)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling
por: Grant, Alice H., et al.
Publicado: (2023)

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M.P., et al.
Publicado: (2017)

Jak2 is required for the initiation but not maintenance of prolactin-induced mammary cancer
por: Sakamoto, Kazuhito, et al.
Publicado: (2010)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation
por: Ferrao, Ryan D, et al.
Publicado: (2018)

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma
por: Costacurta, Matteo, et al.
Publicado: (2020)

Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia
por: Rizzuto, Giuliana, et al.
Publicado: (2022)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
por: Flex, Elisabetta, et al.
Publicado: (2008)

Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis
por: Kelly, Madison J., et al.
Publicado: (2019)

JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies
por: Downes, Charlotte EJ., et al.
Publicado: (2022)

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy
por: Koppikar, Priya, et al.
Publicado: (2012)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility
por: Lin, Minhui, et al.
Publicado: (2019)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

P1029: JAK2-CHIP IS ASSOCIATED WITH SIMILAR RISK OF CARDIOVASCULAR DISEASE AS JAK2-MPN
por: Grevet, Jeremy, et al.
Publicado: (2023)

Crystal structures of the Jak2 pseudokinase domain and the pathogenic mutant V617F
por: Bandaranayake, Rajintha M., et al.
Publicado: (2012)

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
por: McKenney, Anna Sophia, et al.
Publicado: (2018)

Progenitor expansion in apc mutants is mediated by Jak/Stat signaling
por: Lin, Junji, et al.
Publicado: (2011)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

JAK3 Mutations and Mitochondrial Apoptosis Resistance in T-Cell Acute Lymphoblastic Leukemia
por: Bodaar, Kimberly, et al.
Publicado: (2022)

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
por: Ferrao, Ryan, et al.
Publicado: (2017)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Rewriting the mechanism of JAK2 activation
por: Brooks, Andrew J, et al.
Publicado: (2015)

ROCKing the JAKs
por: Peelman, Frank, et al.
Publicado: (2013)

The Jak Tree
Publicado: (1889)

Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction
por: Liu, Chun-Shan, et al.
Publicado: (2017)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAK-STAT signaling and activation of the crosstalk between apoptosis and autophagy signaling
por: Cheng, Zhao, et al.
Publicado: (2017)

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective
por: Staerk, Judith, et al.
Publicado: (2012)

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
por: Luo, Na, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7gcgke1bi451hrmok3iuhduhts